Details

Autor(en) / Beteiligte

• Boluda, Blanca
• Martínez-Cuadrón, David
• Algarra, Lorenzo
• Cano, Isabel
• Sayas, María J.
• Acuña-Cruz, Evelyn
• Blanco, Albert
• Marco-Ayala, Javier
• DeLapuerta, Rosalía
• Díaz-González, Álvaro
• Tormo, Mar
• Rodríguez-Veiga, Rebeca
• García, Raimundo
• Piñana, José L.
• López-Pavía, María
• Barragán, Eva
• Amigo, María L.
• Sargas, Claudia
• López, Aurelio
• Solana-Altabella, Antonio
• Gil, Cristina
• Megías-Vericat, Juan Eduardo
• Sanz, Miguel A.
• Montesinos, Pau

Titel

Evolving patterns of care and outcomes in relapsed/refractory FLT3 mutated acute myeloid leukemia adult patients

Ist Teil von

• Leukemia & lymphoma, 2021-09, Vol.62 (11), p.2727-2736

Ort / Verlag

Taylor & Francis

Erscheinungsjahr

2021

Quelle

Taylor & Francis Journals Auto-Holdings Collection

Beschreibungen/Notizen

• We have analyzed treatment patterns and outcomes of relapsed/refractory(R/R) FLT3mut AML adult patients registered in our institutional data base between 1998 and 2018. Overall, 147 patients were evaluable: 34 from 1998 to 2009, 113 from 2010 to 2018. Salvage treatments were intensive chemotherapy (n = 25, 74%), and supportive care (n = 9, 26%) in the 1998-2009 period, and intensive chemotherapy (n = 63, 56%), hypomethylating agent (n = 7, 6%), low-dose cytarabine-based (n = 8, 7%), clinical trial (n = 16, 14%) and supportive care (n = 19, 17%) in the 2010-2018 period. Complete remission (CR) or with incomplete recovery (CRi) rate was 44%, 49% among patients treated intensively (vs 30% with non-intensive p = 0.005). Median overall survival since first R/R was 5.8 months, and 16.3 months in subjects receiving an allo-HSCT in CR/CRi after first salvage (vs 3.8 in the remaining patients p < 0.0001). Clinical outcomes of R/R FLT3mut AML remain unsatisfactory. Inclusion in clinical trials and expanding options could lead to improved outcomes.